Harbinger Health Introduces RESOLVE for Multi-Cancer Detection

Apr 14, 2026
Harbinger Health has announced RESOLVE, a new category of blood-based multi-cancer detection tests aimed at reducing diagnostic delays and improving clinical decision-making, with commercial availability expected in late 2026.

Cambridge-based Harbinger Health has announced RESOLVE, a new category of blood-based multi-cancer detection tests, according to a press release. The product line aims to address the period between cancer suspicion and diagnosis, with commercial availability planned for the second half of 2026.

The RESOLVE tests are powered by the Harbinger HX platform and are designed to reduce both false negatives and false positives while providing information about the cancer’s tissue of origin. The company stated that these features could enable faster clinical decision-making when cancer is suspected.

Development of the RESOLVE portfolio is supported by a $100 million financing round completed in 2025, led by Flagship Pioneering and existing investors. The funding also supports Harbinger’s ongoing PROCARES prospective validation study and further advancement of the HX platform.

We hope you enjoyed this article

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)
Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Whitepaper

Tensordyne Napier: What If One Rack Could Do the Work of Nine?

Tensordyne

This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.

Read more

You may also like

Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.